Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 5 | 2024 | 293 | 1.440 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 286 | 1.340 |
Why?
|
| Bacteremia | 2 | 2019 | 406 | 0.960 |
Why?
|
| Candida tropicalis | 1 | 2024 | 16 | 0.940 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 19 | 0.940 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 2397 | 0.890 |
Why?
|
| Candidemia | 3 | 2015 | 40 | 0.880 |
Why?
|
| Vancomycin | 3 | 2022 | 217 | 0.870 |
Why?
|
| Mycoses | 2 | 2021 | 117 | 0.820 |
Why?
|
| Mastoiditis | 1 | 2022 | 31 | 0.790 |
Why?
|
| Rat-Bite Fever | 1 | 2021 | 4 | 0.780 |
Why?
|
| Streptobacillus | 1 | 2021 | 4 | 0.780 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2021 | 3 | 0.780 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2021 | 5 | 0.780 |
Why?
|
| Skin Diseases | 1 | 2022 | 122 | 0.750 |
Why?
|
| Near Drowning | 1 | 2021 | 26 | 0.730 |
Why?
|
| Drowning | 1 | 2021 | 32 | 0.720 |
Why?
|
| Procyonidae | 1 | 2020 | 1 | 0.720 |
Why?
|
| Bites and Stings | 1 | 2020 | 30 | 0.700 |
Why?
|
| Cellulitis | 1 | 2020 | 64 | 0.690 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 220 | 0.680 |
Why?
|
| Salmonella Infections | 1 | 2019 | 31 | 0.670 |
Why?
|
| Hand | 1 | 2020 | 102 | 0.670 |
Why?
|
| Abscess | 1 | 2020 | 138 | 0.640 |
Why?
|
| Photorhabdus | 1 | 2018 | 2 | 0.630 |
Why?
|
| Disease Management | 2 | 2021 | 516 | 0.620 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2018 | 23 | 0.610 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 266 | 0.610 |
Why?
|
| Neonatal Sepsis | 1 | 2018 | 29 | 0.600 |
Why?
|
| Child | 16 | 2024 | 24208 | 0.480 |
Why?
|
| Amphotericin B | 2 | 2022 | 90 | 0.450 |
Why?
|
| Infant | 10 | 2024 | 12323 | 0.450 |
Why?
|
| Child, Preschool | 11 | 2024 | 13862 | 0.440 |
Why?
|
| Retrospective Studies | 10 | 2024 | 15979 | 0.410 |
Why?
|
| Adolescent | 11 | 2024 | 19086 | 0.370 |
Why?
|
| Candida | 1 | 2011 | 75 | 0.370 |
Why?
|
| Bartonella | 1 | 2010 | 10 | 0.360 |
Why?
|
| Bartonella Infections | 1 | 2010 | 7 | 0.360 |
Why?
|
| Retinitis | 1 | 2010 | 17 | 0.350 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 798 | 0.320 |
Why?
|
| Female | 17 | 2024 | 65427 | 0.310 |
Why?
|
| Humans | 22 | 2024 | 123190 | 0.290 |
Why?
|
| Male | 14 | 2024 | 60020 | 0.270 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8089 | 0.250 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 25 | 0.240 |
Why?
|
| Cough | 1 | 2023 | 86 | 0.210 |
Why?
|
| Pleural Effusion | 1 | 2023 | 100 | 0.210 |
Why?
|
| Phaeohyphomycosis | 1 | 2022 | 11 | 0.210 |
Why?
|
| Cerebral Ventriculitis | 1 | 2022 | 15 | 0.210 |
Why?
|
| Central Nervous System Infections | 1 | 2022 | 21 | 0.200 |
Why?
|
| Incidence | 2 | 2024 | 3050 | 0.190 |
Why?
|
| Cephalosporins | 1 | 2022 | 138 | 0.190 |
Why?
|
| Arthritis, Infectious | 1 | 2021 | 60 | 0.180 |
Why?
|
| Exanthema | 1 | 2021 | 68 | 0.180 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2020 | 4 | 0.180 |
Why?
|
| Pets | 1 | 2020 | 15 | 0.180 |
Why?
|
| Fusobacterium nucleatum | 1 | 2020 | 24 | 0.180 |
Why?
|
| Risk Factors | 4 | 2024 | 10001 | 0.180 |
Why?
|
| Clinical Clerkship | 1 | 2020 | 90 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 730 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 143 | 0.160 |
Why?
|
| Fever | 1 | 2021 | 296 | 0.160 |
Why?
|
| Acute Disease | 1 | 2022 | 1090 | 0.160 |
Why?
|
| HIV Infections | 1 | 2010 | 1868 | 0.150 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 169 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2019 | 313 | 0.150 |
Why?
|
| Ceftazidime | 1 | 2018 | 41 | 0.150 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 102 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2021 | 484 | 0.140 |
Why?
|
| Rhinitis | 1 | 2017 | 38 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 499 | 0.130 |
Why?
|
| Sinusitis | 1 | 2017 | 117 | 0.130 |
Why?
|
| Students, Medical | 1 | 2020 | 361 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2018 | 365 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 376 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2018 | 470 | 0.120 |
Why?
|
| Rats | 1 | 2021 | 3631 | 0.120 |
Why?
|
| Body Weight | 1 | 2019 | 999 | 0.120 |
Why?
|
| Algorithms | 1 | 2021 | 1597 | 0.120 |
Why?
|
| Hypokalemia | 1 | 2012 | 41 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 280 | 0.100 |
Why?
|
| Kidney | 1 | 2018 | 1338 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 608 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12102 | 0.090 |
Why?
|
| Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2010 | 2 | 0.090 |
Why?
|
| Organophosphonates | 1 | 2010 | 19 | 0.090 |
Why?
|
| Oxazines | 1 | 2010 | 25 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 410 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1011 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3518 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2010 | 77 | 0.090 |
Why?
|
| Adenine | 1 | 2010 | 99 | 0.090 |
Why?
|
| Animals | 2 | 2021 | 33740 | 0.080 |
Why?
|
| Doxycycline | 1 | 2010 | 117 | 0.080 |
Why?
|
| Lung | 2 | 2023 | 1469 | 0.080 |
Why?
|
| Rifampin | 1 | 2010 | 146 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 271 | 0.080 |
Why?
|
| Time Factors | 1 | 2019 | 6201 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3260 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2012 | 478 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 305 | 0.070 |
Why?
|
| Biopsy | 1 | 2010 | 1239 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 2767 | 0.060 |
Why?
|
| Texas | 1 | 2011 | 3548 | 0.050 |
Why?
|
| Ascomycota | 1 | 2022 | 25 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 149 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 8868 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2022 | 253 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 564 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1230 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 991 | 0.040 |
Why?
|
| Nafcillin | 1 | 2018 | 14 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 13 | 0.040 |
Why?
|
| Clindamycin | 1 | 2018 | 40 | 0.040 |
Why?
|
| Acetazolamide | 1 | 2018 | 30 | 0.040 |
Why?
|
| Learning | 1 | 2020 | 361 | 0.040 |
Why?
|
| Debridement | 1 | 2017 | 85 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 619 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 455 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 2043 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 283 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 500 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1799 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1004 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1995 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 1023 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3662 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 29 | 0.020 |
Why?
|
| Camptothecin | 1 | 2006 | 76 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 234 | 0.020 |
Why?
|
| Middle Aged | 2 | 2018 | 25976 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 649 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 29035 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1470 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 1216 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1684 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5047 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 3332 | 0.010 |
Why?
|
| Aged | 1 | 2006 | 19068 | 0.000 |
Why?
|